Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →
| Conto economico | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrate totali | $5.8B | $5.1B | $4.2B | $3.7B | $3.4B | $3.0B | $2.7B | $2.2B | $1.9B | $1.5B | $1.1B | $754M | $511M | $355M | $297M | $94M | $170M | $9M | $4M | $34M | $28M |
| Utile lordo | $5.4B | $4.8B | $3.9B | $3.4B | $3.2B | $2.8B | $2.5B | $2.0B | $1.8B | $1.5B | $1.0B | $727M | $508M | $354M | $297M | $94M | $170M | $9M | $4M | $34M | $28M |
| Margine lordo% | 92.6% | 92.8% | 92.6% | 93.1% | 93.9% | 94.9% | 95.1% | 94.7% | 95.0% | 94.8% | 94.7% | 96.4% | 99.4% | 99.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Risultato Operativo (EBIT) | $1.8B | $1.3B | $101M | $655M | $592M | $586M | ($264M) | $402M | $129M | ($243M) | $145M | $51M | ($5M) | ($16M) | $1M | ($143M) | $14M | ($140M) | ($159M) | ($85M) | ($77M) |
| Margine operativo % | 31.6% | 26.1% | 2.4% | 17.7% | 17.4% | 19.6% | -9.9% | 18.6% | 6.9% | -15.8% | 13.1% | 6.7% | -0.9% | -4.5% | 0.4% | -151.6% | 8.3% | -1508.6% | -4064.5% | -247.6% | -278.1% |
| Reddito netto | $1.6B | $1.3B | $33M | $598M | $341M | $949M | ($296M) | $447M | $109M | ($313M) | $104M | $7M | ($48M) | ($83M) | ($44M) | ($187M) | ($32M) | ($212M) | ($179M) | ($87M) | ($74M) |
| Margine netto% | 27.7% | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | -11.1% | 20.7% | 5.8% | -20.4% | 9.4% | 0.9% | -9.5% | -23.4% | -14.9% | -197.5% | -18.8% | -2286.8% | -4565.4% | -252.3% | -268.3% |
| EBITDA | — | $1.8B | $408M | $919M | $600M | $630M | ($178M) | $543M | $172M | ($253M) | $205M | $98M | $40M | ($15M) | $32M | ($116M) | $36M | ($123M) | ($146M) | ($72M) | ($69M) |
| Utile per azione (EPS) | $7.85 | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 | $0.03 | $-0.29 | $-0.56 | $-0.34 | $-1.49 | $-0.26 | $-2.06 | $-1.99 | $-1.03 | $-0.89 |
| Azioni in circolazione (M) | — | 201M | 211M | 226M | 224M | 222M | 218M | 218M | 216M | 205M | 194M | 187M | 168M | 148M | 130M | 125M | 122M | 103M | 90M | 84M | 84M |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di INCY. /companies/us/INCY
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms